Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Status Completed

Clinical Trial Summary

The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy). The major objective of this study is to determine the progression free survival. The goal is to prevent relapse or recurrence of their uterine leiomyosarcoma.

Clinical Trial Description

Patients with a diagnosis of early-stage uterine leiomyosarcoma have a 70% chance of relapse or recurrence of their disease. Patients enrolled in this trial will receive 4 cycles of gemcitabine and docetaxel followed by 4 cycles of adriamycin. Following completion of chemotherapy, they will be have repeat imaging at regular intervals to monitor for disease recurrence along with periodic clinical evaluations. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00282087
Study type	Interventional
Source	Sarcoma Alliance for Research through Collaboration
Contact
Status	Completed
Phase	Phase 2
Start date	January 2006
Completion date	January 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT04535271` - Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma	Phase 2
Recruiting	`NCT06088290` - Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma	Phase 2/Phase 3
Withdrawn	`NCT04906876` - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas	Phase 2
Terminated	`NCT02940041` - Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
Completed	`NCT01442662` - Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine	Phase 2
Completed	`NCT00062868` - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma	Phase 1
Recruiting	`NCT04214457` - Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
Active, not recruiting	`NCT04420975` - Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma	Phase 1
Terminated	`NCT04099277` - A Study of LY3435151 in Participants With Solid Tumors	Phase 1
Not yet recruiting	`NCT05548179` - Exploring Clinical Trial Experiences of People With Leiomyosarcoma
Recruiting	`NCT02983539` - Detection of Circulating Tumor Cells in Patients With Sarcomas
Completed	`NCT00093080` - Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)	Phase 2
Active, not recruiting	`NCT04624178` - A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma	Phase 2
Terminated	`NCT03959033` - Patient Reported Outcome Measures (PROMs) With Trabectedin
Recruiting	`NCT02275286` - Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients	Phase 1/Phase 2
Active, not recruiting	`NCT01956084` - Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma	Phase 1
Completed	`NCT01426633` - Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas	Phase 1
Completed	`NCT00400569` - Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma	Phase 2
Recruiting	`NCT05080790` - Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma	Phase 2